Ashland Opens a Pharmaceutical Center in Delaware
Ashland Specialty Ingredients opened a drug development and bioavailability enhancement facility in Wilmington, Delaware.
Ashland Specialty Ingredients opened a facility to focus on drug development, bioavailability enhancement, and contract development for solid dispersions and oral solid-dosage forms. The facility is located in Wilmington, Delaware and has capabilities including spray drying, hot-melt extrusion, and potent-compound processing suites.
"Research and development (R&D) dedicated to drug development and bioavailability enhancement is essential to the future success of the pharmaceutical manufacturing industry. Emerging manufacturing processes, such as continuous manufacturing by spray drying or hot-melt extrusion, is one component of this equation. Excipients science is another,” said Jim Mish, group vice president, Consumer Specialties, Ashland Specialty Ingredients in a press release. “At our new center of excellence, we will be combining our expertise in process technology along with our knowledge in materials science to further support the quality, safety and efficiency of oral solid-dosage forms.”
Ashland Specialty Ingredients is focused on solutions in the pharmaceutical and nutraceutical industries. It now has 10 centers around the world for research, development, and technical support.
Source: Ashland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
